成人囊性纤维化急性加重期基于身高的妥布霉素给药方案评估
本研究在加拿大魁北克独立数据集中外部验证了3个妥布霉素群体药代动力学模型,并用蒙特卡洛模拟评估基于身高的给药方案。Crass等和Alghanem等模型预测性能可接受,模拟显示每日一次3.4 mg/cm给药可使峰谷浓度符合现行指南。
要点
- Crass等和Alghanem等模型外部验证预测性能可接受。
- 模拟显示每日一次3.4 mg/cm给药峰谷浓度符合指南。
- 基于身高的给药方案可考虑用于囊性纤维化患者。
核心结论
- Crass等和Alghanem等模型适合模拟应用以辅助本群体个体化给药。
- 囊性纤维化患者可考虑基于身高的妥布霉素给药方案。
研究设计与样本
- 通过PubMed检索文献识别相关群体药代动力学模型。
- 验证数据集包括27例患者和143份浓度样本。
- 使用NONMEM v7.5和RStudio v1.3.1073进行外部评估和蒙特卡洛模拟。
主要发现
- 共评估3个模型,仅Crass等和Alghanem等模型预测诊断表现满意。
- Crass等模型MDPE为-3.4%,MDAPE为19.0%。
- Alghanem等模型MDPE为29.3%,MDAPE为29.5%。
- 模拟评估中pcVPC和NPDE均未显示模型错误设定证据。
关键数值与推荐
- 模拟提示每日一次3.4 mg/cm给药产生的峰谷浓度与现行指南一致。
临床怎么用
- 可参考Crass等和Alghanem等模型进行模拟辅助个体化给药。
- 囊性纤维化患者可考虑基于身高的妥布霉素给药方案。
局限性
- 外部验证数据集样本量较小(27例患者、143份样本)。
- 仅评估3个模型,外推至其他临床中心需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Some population pharmacokinetic models have been developed using height to explain some of the interindividual variability in tobramycin pharmacokinetics in cystic fibrosis patients. However, their predictive performance when extrapolated to other clinical centres is unclear. Therefore, the aim of this study was to externally evaluate the predictability of tobramycin population pharmacokinetic models with an independent dataset and perform simulations using previously recommended height-based dosing regimens. METHODS: A literature search was conducted through the PubMed database to identify relevant population pharmacokinetic models. Tobramycin plasma concentration data from April 2014 to November 2019 were retrospectively collected from the Institut universitaire de cardiologie et de pneumologie de Québec, Canada. External evaluations were performed using NONMEM® v7.5 and RStudio® v1.3.1073. Monte Carlo simulations were performed to evaluate the probability of target attainment of Cmax /MIC ratios for several dosing regimens. RESULTS: The validation dataset included 27 patients and 143 concentration samples. Three models were evaluated. Only the ones by Crass et al. and Alghanem et al. performed satisfactorily in terms of prediction-based diagnostics with MDPE values of -3.4% and 29.3% and MDAPE values of 19.0 and 29.5%, respectively. In simulation-based evaluations, both pcVPC and NPDE showed no evidence of model misspecification. Our simulations suggest that patients treated with a once-daily dose of 3.4 mg/cm should produce peak and trough levels consistent with current guidelines. CONCLUSION: Our results show that the models by Crass et al. and Alghanem et al. are appropriate for simulation-based applications to aid individualized dosing in our population and that height-based dosing regimens could be considered in cystic fibrosis patients.
引用
- El Hassani M, Simard C, Pilote S, et al. Consideration of height-based tobramycin dosing regimens for the treatment of adult cystic fibrosis pulmonary exacerbations. Br J Clin Pharmacol. 2021. PMID: 34820875. doi:10.1111/bcp.15154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。